Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
One step forward, two steps back for biotech.
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.
Tough equity markets as well as competitor developments prompt a narrowed focus.
Another SERD catalyst and the son of Darzalex take centre stage.
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
